A paradigm shift driven by higher regulatory standards, standards is transforming the medical aesthetics ecosystem by enhancing treatment precision, accuracy and reliability, influencing patient behaviour, improving their decision-making process, and optimising their experiential journey.
A paradigm shift driven by higher regulatory standards, standards is transforming the medical aesthetics ecosystem by enhancing treatment precision, accuracy and reliability, influencing patient behaviour, improving their decision-making process, and optimising their experiential journey. We are witnessing an unprecedented rise in the use of skinboosters, biostimulators, and new types of fillers and tissue inducers (PLLA, PDLA, PMMA, PCL, PCA, PDRN, PN, and combinations). More sophisticated patients are seeking treatments to look younger, and they now have access to more information than ever before about properties such as elasticity, cohesiveness, plasticity, ease of injection, and longevity of results, as well as the widespread availability of these standards. Starting in markets at the forefront of scientific breakthroughs, such as Korea, California, Israel, and coastal regions of China, the phenomenon is spreading to advanced markets through social media, which amplifies this surge, and is gaining momentum in emerging countries.
This is also fuelled by the exponential increase in deep wrinkle treatments following the irresistibly growing use in the US, and soon Europe and China of GLP-1 analogues for fat-loss, such as NovoNordisk’s Ozempic or Wegovy, as well as treatments for metabolic syndrome such as Lilly’s Zepbound or Mounjaro. It should be noted that 70% of US-based medical aesthetic centres have started to prescribe GLP-1 analogues to their obese and overweight patients. This need for quick results and interest in ingredients that help rejuvenate tissue is also driving demand for exosomes, especially those derived from stem cells or plant progenitor cells. This is leading to the emergence of key players, evidenced by M&A and IPOs, such as Exocobio’s acquisition of Benev, Archimed’s purchase of Cellese, and Carmell Therapeutics or Elevai Skincare’s IPOs.
